ASSOCIATION OF FIBROTIC CHANGES IN LIVER ON FIBRO-SCAN WITH VIRAL LOAD IN HEPATITIS C POSITIVE PATIENTS - A PILOT SUDY

Authors

  • Muhammad Arshad The Institute of Nuclear Medicine, Oncology and Radiotherapy, Abbottabad
  • Iqra Manzoor University Institue of Radiological Sciences and Medical Imaging Technology, Lahore
  • Khalid Hussain Memon University Institue of Radiological Sciences and Medical Imaging Technology, Lahore
  • Asif Haider University Institue of Radiological Sciences and Medical Imaging Technology, Lahore
  • Umer Aziz Khan NIMS Teaching Hospital Abbottabad
  • Iraj Nayab Hazara University, Mansehra
  • Zareen Fatima University Institue of Radiological Sciences and Medical Imaging Technology, Lahore

DOI:

https://doi.org/10.55519/JAMC-01-11171

Keywords:

Cirrhosis, Fibroscan, Hepatic events, Liver stiffness measurement Fibrosis

Abstract

Background: Hepatitis C is a diverse illness that causes significant death and morbidity. The hepatitis C virus infects hundreds of millions of individuals globally (HCV). More than 80% of those infected develop chronic infection; the remaining 10–20% recover spontaneously through natural immunity. Acute hepatitis is only icteric in 20% of individuals and is seldom severe. Methods: A pilot study was conducted at INOR hospital Abbottabad. Eleven hepatitis C positive and 10 hepatitis C negative participants were included in the study. Results: A significant difference correlation was found between viral load and SWE quantification for fibrosis stage in Kilo-Pascal, r= 0.904 (p-value=0.000 <a=0.05). HCV positive patients showed a viral load of (Mean±SD) 128,185.8±153,719.1. Conclusion: Although a biopsy is considered to be gold standard for determining the degree of damage caused by chronic viral hepatitis, it is far from perfect. Liver elastography is an intriguing technique that can help physicians make difficult decisions while treating viral hepatitis. This study showed that fibrotic changes of liver are directly proportional to the presence of viral load in blood. The greater the viral load more severe fibrosis will be seen. Age also plays a role in severity of fibrosis, however, more studies on larger population is required to support this statement.

Author Biographies

Muhammad Arshad, The Institute of Nuclear Medicine, Oncology and Radiotherapy, Abbottabad

Technologist Radiology INOR

Iqra Manzoor, University Institue of Radiological Sciences and Medical Imaging Technology, Lahore

 

Khalid Hussain Memon, University Institue of Radiological Sciences and Medical Imaging Technology, Lahore

 

Asif Haider, University Institue of Radiological Sciences and Medical Imaging Technology, Lahore

 

Umer Aziz Khan, NIMS Teaching Hospital Abbottabad

 

Iraj Nayab, Hazara University, Mansehra

 

Zareen Fatima, University Institue of Radiological Sciences and Medical Imaging Technology, Lahore

 

References

Zhang HC, Zhu T, Hu RF, Wu L. Contrast-enhanced ultrasound imaging features and clinical characteristics of combined hepatocellular cholangiocarcinoma: comparison with hepatocellular carcinoma and cholangiocarcinoma. Ultrasonography 2020 ;39(4):356–66.

Du Y, Fang Z, Jiao BJ, Xi G, Zhu C, Ren Y, et al. Application of ultrasound‐based radiomics technology in fetal lung texture analysis in pregnancies complicated by gestational diabetes or pre‐eclampsia. Ultrasound Obstet Gynecol 2021;57(5):804–12.

Wei Y, Gao F, Zheng D, Huang Z, Wang M, Hu F, et al. Intrahepatic cholangiocarcinoma in the setting of HBV-related cirrhosis: Differentiation with hepatocellular carcinoma by using Intravoxel incoherent motion diffusion-weighted MR imaging. Oncotarget 2018;9(8):7975–83.

Wu W, Chen J, Bai C, Chi Y, Du Y, Feng S, et al. The Chinese guidelines for the diagnosis and treatment of pancreatic neuroendocrine neoplasms (2020). Zhonghua Wai Ke Za Zhi 2021;59(6):401–21.

Malone CD, Fetzer DT, Monsky WL, Itani M, Mellnick VM, Velez PA, et al. Contrast-enhanced US for the interventional radiologist: Current and emerging applications. Radiographics 2020;40(2):562–88.

Fattovich G, Giustina G, Schalm SW, Hadziyannis S, Sanchez-Tapias J, Almasio P, et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP study group on hepatitis B virus cirrhosis. Hepatology 1995;21(1):77–82.

Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001;344(7):495–500.

Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002;97(10):2614–8.

Foucher J, Chanteloup E, Vergniol J, Castera L, Le Bail B, Adhoute X, et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 2006;55(3):403–8.

Ganne‐Carrié N, Ziol M, de Ledinghen V, Douvin C, Marcellin P, Castera L, et al. Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology 2006;44(6):1511–7.

Kazemi F, Kettaneh A, N’kontchou G, Pinto E, Ganne-Carrie N, Trinchet JC, et al. Liver stiffness measurement selects patients with cirrhosis at risk of bearing large oesophageal varices. J Hepatol 2006;45(2):230–5.

Kim BK, Han KH, Park JY, Ahn SH, Kim JK, Paik YH, et al. A liver stiffness measurement-based, noninvasive prediction model for high-risk esophageal varices in B-viral liver cirrhosis. Am J Gastroenterol 2010;105(6):1382–90.

Jung KS, Kim SU, Ahn SH, Park YN, Kim DY, Park JY, et al. Risk assessment of hepatitis B virus–related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology 2011;53(3):885–94.

Harrison SA. Utilization of FibroScan testing in hepatitis C virus management. Gastroenterol Hepatol (N Y) 2015;11(3):187–9.

Arthur R, Imam I, Saad M, Hackbart B, Mossad S. HCV in Egypt in 1977. Lancet 1995;346(8984):1239–40.

Anjum S, Ali S, Ahmad T, Afzal MS, Waheed Y, Shafi T, Ashraf M, Andleeb S. Sequence and structural analysis of 3'untranslated region of hepatitis C virus, genotype 3a, from Pakistani isolates. Hepat Mon 2013;13(5):e8390.

Köse Ş, Kuzucu L, Gözaydın A, Yılmazer T. Prevalence of hepatitis B and C viruses among asylum seekers in Izmir. J Immigr Minor Health 2015;17(1):76–8.

Gasim GI, Murad IA, Adam I. Hepatitis B and C virus infections among pregnant women in Arab and African countries. J Infect Dev Ctries 2013;7(8):566–78.

Noubiap JJ, Joko WY, Nansseu JR, Tene UG, Siaka C. Sero-epidemiology of human immunodeficiency virus, hepatitis B and C viruses, and syphilis infections among first-time blood donors in Edéa, Cameroon. Int J Infect Dis 2013;17(10):e832–7.

Waheed Y, Shafi T, Safi SZ, Qadri I. Hepatitis C virus in Pakistan: a systematic review of prevalence, genotypes and risk factors. World J Gastroenterol 2009;15(45):5647–53.

Muzaffar F, Hussain I, Haroon TS. Hepatitis C: the dermatologic profile. J Pak Assoc Dermatol 2008;18(3):171–81.

Yosry A, Fouad R, Alem SA, Elsharkawy A, El-Sayed M, Asem N, et al. FibroScan, APRI, FIB4, and GUCI: Role in prediction of fibrosis and response to therapy in Egyptian patients with HCV infection. Arab J Gastroenterol 2016;17(2):78–83.

Pradat P, Voirin N, Tillmann HL, Chevallier M, Trepo C. Progression to cirrhosis in hepatitis C patients: an age-dependent process. Liver Int 2007;27(3):335–9.

Alboraie M, Khairy M, Elsharkawy M, Asem N, Elsharkawy A, Esmat G. Value of Egy-Score in diagnosis of significant, advanced hepatic fibrosis and cirrhosis compared to aspartate aminotransferase-to-platelet ratio index, FIB-4 and Forns’ index in chronic hepatitis C virus. Hepatol Res 2015;45(5):560–70.

Papastergiou V, Tsochatzis E, Burroughs AK. Non-invasive assessment of liver fibrosis. Ann Gastroenterol 2012;25(3):218–31.

Marcellin P, Ziol M, Bedossa P, Douvin C, Poupon R, de Lédinghen V, et al. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int 2009;29(2):242–7.

Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128(2):343–50.

Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003;29(12):1705–13.

Adhoute X, Foucher J, Laharie D, Terrebonne E, Vergniol J, Castéra L, et al. Diagnosis of liver fibrosis using FibroScan and other noninvasive methods in patients with hemochromatosis: a prospective study. Gastroenterol Clin Biol 2008;32(2):180–7.

Kelleher T, MacFarlane C, de Ledinghen V, Beaugrand M, Foucher J, Castera L, et al. Risk factors and hepatic elastography (FibroScan) in the prediction of hepatic fibrosis in non-alcoholic steatohepatitis. Gastroenterology. 2006;130(4):A768.

Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005;41(1):48–54.

Ogawa E, Furusyo N, Toyoda K, Takeoka H, Otaguro S, Hamada M, et al. Transient elastography for patients with chronic hepatitis B and C virus infection: Non-invasive, quantitative assessment of liver fibrosis. Hepatol Res 2007;37(12):1002–10.

Corpechot C, El Naggar A, Poujol-Robert A, Ziol M, Wendum D, Chazouillères O, et al. Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology 2006;43(5):1118–24.

Sporea I, Sirli R, Deleanu A, Tudora A, Curescu M, Cornianu M, et al. Comparison of the liver stiffness measurement by transient elastography with the liver biopsy. World J Gastroenterol 2008;14(42):6513–7.

Yoneda M, Yoneda M, Mawatari H, Fujita K, Endo H, Iida H, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis 2008;40(5):371–8.

Kim KM, Choi WB, Park SH, Yu E, Lee SG, Lim YS, et al. Diagnosis of hepatic steatosis and fibrosis by transient elastography in asymptomatic healthy individuals: a prospective study of living related potential liver donors. J Gastroenterol 2007;42(5):382–8.

Berends MA, Snoek J, de Jong EM, Van Krieken JH, de Knegt RJ, van Oijen MG, et al. Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan predicts the absence of significant liver fibrosis. Liver Int 2007;27(5):639–45.

Lupşor M, Badea R, Stefănescu H, Grigorescu M, Sparchez Z, Serban A, et al. Analysis of histopathological changes that influence liver stiffness in chronic hepatitis C. Results from a cohort of 324 patients. J Gastrointestin Liver Dis 2008;17(2):155–63.

Coco B, Oliveri F, Maina AM, Ciccorossi P, Sacco R, Colombatto P, et al. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J Viral Hepat 2007;14(5):360–9.

Friedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, Zeuzem S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008;134(4):960–74.

Castera L, Le Bail B, Foucher J, Bertet J, Darriet M, Couzigou P, et al. Prospective analysis of discordance between FibroScan and FibroTest when used in combination as first-line assessment of liver fibrosis in chronic hepatitis C. Hepatology 2005;42(Suppl 1):440A.

Blanc PL, Gabbuti A, Marino N, Mecocci L, Mazzotta F. Liver stiffness in chronic hepatitis C: will it modify the assessment of patients? J Hepatol 2007;46(Suppl 1):S201–2.

Seo YS, Kim ES, Kwon YD, Park S, Keum B, Park BJ, et al. Liver stiffness measurement in patients with chronic hepatitis B is not as useful as that in patients with chronic hepatitis C for the assessment of liver fibrosis. Hepatology. 2007;46(Suppl 4):842A.

Downloads

Published

2023-01-15

Most read articles by the same author(s)